Clinical Trial Update: Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease [Phase 2]

View source ↗

Summary

Phase 2 proof-of-mechanism study of MLN1202 in stable atherosclerotic cardiovascular disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• MLN1202

Snippet

Sponsor: Takeda | Conditions: Atherosclerotic Cardiovascular Disease | Phase 2 | Status: WITHDRAWN